Respiratory syncytial virus having altered NS1 protein function and related materials and methods

US10947512B2 · kind B2 · utility

Assignees

• Research Institute at Nationwide Children's Hospital · US
• University of South Florida · US

Inventors

• Mark E. Peeples · Bexley, US
• Michael N. Teng · Rockville, US
• Octavio Ramilo · Columbus, US
• Maria Asuncion Mejias · Columbus, US
• Emilio Flano · Needham, US

Key dates

• Filing date: Aug 12, 2016
• Grant date: Mar 16, 2021
• Expiry date: Aug 12, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having a mutated NS1 protein, where the mutation causes the uncoupling of the NS1 protein's replication and type I interferon (IFN) antagonist functions. In some embodiments, this uncoupling can produce virions capable of inducing a strong, long-lasting innate immune response while maintaining its ability to replicate in vitro. Also provided are methods for amplifying RSV in host cells, wherein amplified RSV has mutated NS1 protein in which the protein's replication and IFN antagonistic functions are uncoupled. In certain embodiments, the amplified RSV having mutated NS1 protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.